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Purpose: To investigate the ultrasonographic (US) features of anaplastic thyroid 
cancer (ATC) and the diagnostic performance of US-guided fine needle aspiration 
biopsy (FNAB) therein. Materials and Methods: Eighteen cases of ATC diag-
nosed between January 2001 and May 2011 were included. FNAB was performed 
in all cases. Initial FNAB results were divided into three groups: 1) the cytological 
ATC group, cytological diagnosis of ATC; 2) the underestimated group, cytological 
diagnoses of malignancy other than ATC; and 3) the false negative group, cytologi-
cal diagnoses of atypical, benign and non-diagnostic lesions. We retrospectively re-
viewed US findings and compared treatment modalities between each group. Re-
sults: Among the 18 patients, there were nine in the initially cytological ATC group, 
four in the underestimated group and five in the false negative group. The most 
common US features of ATC were a solid (64.7%) and irregular shaped (88.2%) 
mass with lymph node involvement (76.4%). However, except for lymph node in-
volvement (p=0.003), US findings for each group were not statistically different. 
The initial cytological diagnostic accuracy of ATC was 50% (9/18). Surgery was 
performed less in the ATC group (11%) and the false negative group (20%) than the 
underestimated group (75%). Conclusion: The US features of ATC were not espe-
cially different from other types of aggressive thyroid cancer. A correct diagnosis of 
ATC by initial US-FNAB was made in 50% of the patients, which is significant in 
that therapeutic surgery can be undertaken in lower numbers if correctly diagnosed.
Key Words:   Anaplastic thyroid cancer, fine needle aspiration biopsy, ultrasonog-
raphy
INTRODUCTION
Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer, with 
median survival on the order of 3 to 5 months following diagnosis.1-4 Even though 
less than 1-3% of all thyroid cancers are ATC, it contributes to 14-50% of the annu-
al mortality associated with thyroid cancer.5-7 The treatment for ATC has not been 
standardized because therapy has not been conclusively proven to be effective in 
prolonging survival. Until now, surgery has played an important role in survival for 
patients with intrathyroidal tumors.8-10 However, many patients have also presented 
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of six radiologists with 1 to 14 years of experience in thy-
roid imaging. US-FNAB was performed with a 23-gauge 
needle attached to a 20-mL disposable plastic syringe and 
aspirator or a 2-mL syringe disposable plastic syringe. As-
pirated materials were expelled on glass slides and immedi-
ately fixed in 95% alcohol for Papanicolaou staining. The 
remaining material in the syringe was rinsed in normal sa-
line for cell block processing. US-guided core biopsy was 
performed using a freehand technique, and each procedure 
was performed with a 18-gauge dual-action semiautomatic 
core biopsy needle (Stericut with coaxial; TSK Laboratory, 
Tochigi, Japan). A cytopathologist was not on site during 
the aspiration procedure. Additional special staining was 
performed according to the requirements set by the cytolo-
gist. From 2001 to December 2009, cytology reports were 
divided into the following categories: 1) nondiagnostic 2) 
benign 3) indeterminate 4) suspicious for malignancy and 
5) malignant. Afterwards, the Bethesda classification was 
used to classify cytology results at our institution.20
Data analysis
Each US image was reviewed retrospectively by two radi-
ologists in consensus. US images were reviewed according 
to size, composition, echogenicity, margin, presence of cal-
cification, shape and presence of lymph node involvement. 
Lymph node involvement was considered pathologic if any 
one of the following suspicious features were present: round 
shape, increased echogenicity, cystic change, or presence of 
microcalcifications.21  
To evaluate cytological diagnostic accuracy for ATC, 
FNAB results were divided into three groups: 1) the cyto-
logical ATC group, cytological diagnosis of ATC; 2) the un-
derestimated group, cytological diagnoses of malignancy 
rather than ATC, such as suspicious for papillary carcino-
ma, papillary carcinoma, and poorly differentiated carcino-
ma; and 3) the false negative group, cytological diagnoses 
of atypical, benign and non-diagnostic lesions. We included 
atypia in the false negative group, because the Bethesda sys-
tem recommends follow-up FNAB for patients with atypia 
instead of surgery.20 We compared US findings between 
these three groups. 
For statistical analysis, the SPSS statistical package, ver-
sion 11.0, for Windows (SPSS Inc., Chicago, IL, USA) was 
used. Pearson chi square tests and Fisher’s exact tests were 
used to study categorical variables and the Kruskal-Wallis 
test was used to compare continuous variables. p-values < 
0.005 were considered statistically significant.
with inoperable disease; macroscopic complete resection is 
only possible in up to one-third of patients at presenta-
tion.11-14 The best survival results have been observed in in-
operable patients who received primary chemotherapy and 
radiation therapy rather than primary surgical resection.10,15 
Therefore, an accurate preoperative diagnosis of ATC may 
help avoid unnecessary surgery and allow treatment to pro-
ceed directly to medical therapy.4,16 
A diagnosis of ATC is usually suspected on clinical ex-
amination and ultrasonography (US), which can be con-
firmed by fine needle aspiration biopsy (FNAB), core biop-
sy or surgery. US and the following FNAB are the first di-
agnostic modalities in the evaluation of a palpable thyroid 
mass.17 Several studies have focused on the treatment mo-
dalities or outcomes of ATC,1,4,9,11,14,15,18,19 but there have 
been few reports about US features and the role of preoper-
ative US-guided biopsy in ATC. 
The purpose of this study was to investigate the US fea-
tures of ATC and the diagnostic performance of US-guided 
FNAB. 
MATERIALS AND METHODS
　　　
This retrospective study was conducted with institutional re-
view board approval and patient informed consent was 
waived.
Study population 
From January 2001 to May 2011, a total 18 patients were 
diagnosed as having ATC by US-FNAB, core biopsy and 
surgery at our institution and were included in this study. 
Initially, all patients had undergone US-FNAB of thyroid 
masses. According to the initial FNAB results, patients un-
derwent follow up FNAB (n=2), core biopsy (n=3), diag-
nostic surgery (n=1) and other treatment options including 
medical treatment or therapeutic surgery (n=3). Among the 
18 patients, 5 were men and 13 were women, with ages 
ranging from 54-81 years (mean age 70.5 years). All pa-
tients complained of having a palpable neck mass.
Imaging and diagnostic processes
US was performed before FNAB in all 18 patients with a 
7-15 MHz linear array transducer (HDI 3000 or 5000; Phil-
ips Medical Systems, Bothell, WA, USA) or 5-12 MHz lin-
ear array transducer (Iu22; Philips Medical Systems). Real-
time US and subsequent US-FNAB was performed by one 
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and it increased to 72% (13/18) if the underestimated group 
was regarded as part of the correct diagnostic group. Among 
the 4 patients in the underestimated group, one case of sus-
picious papillary carcinoma was diagnosed as ATC by fol-
low-up core biopsy, and three cases of poorly differentiated 
thyroid carcinoma (PDTC) that underwent surgery were fi-
nally diagnosed as ATC. Among the 5 patients in the false 
negative group, one atypia case and one non-diagnostic case 
were diagnosed as ATC by follow-up core biopsy; two be-
nign cases were diagnosed as ATC by repeat FNAB and one 
benign case was determined to be ATC after surgery (Fig. 
1). Accordingly, a preoperative diagnosis of ATC was made 
in 14 out of 18 cases (77.8%). The mean number of days 
from first visit to confirmative diagnosis of ATC was 10 
days for the ATC group, 33.5 days for the underestimate 
group and 104.5 days for the false negative group. 
US images were available in 17 out of 18 patients. US 
features of the 17 ATC patients according to the three groups 
above are summarized in Table 1. Mean age and mass size 
were not statistically different between each group. The com-
mon US features of ATCs were solid (11/17, 64.7%), marked 
RESULTS
 
Among the 18 patients, there were nine in the initially cyto-
logical ATC group; four in the underestimated group, poor-
ly differentiated cancer (n=3) and suspicious papillary car-
cinoma (n=1); and five in the false negative group, atypia 
(n=1), benign (n=3), and non-diagnostic (n=1). The initial 
cytological diagnostic accuracy of ATC was 50% (9/18) 
Fig. 1. Preoperative diagnostic methods of 18 anaplastic ATC. Underestimated 
group: poorly differentiated cancer and suspicious papillary carcinoma. 
False negative group: atypia, benign and non-diagnostic. bx, biopsy; ATC, 
anaplastic thyroid cancer; FNAB, fine needle aspiration biopsy.
Table 1. Ultrasonographic Findings of Anaplastic Thyroid Cancers According to Three Groups
ATC (n=8) Underestimate (n=4) False negative (n=5) p value
Diameter (mm) 48.5 49.5 40.4 0.330
Age (yrs)                       76.3 63.5 67.4 0.322
US features
    Composition 0.262
        Solid    7 (87.5%)    2 (50.0%)    2 (40.0%)
        Mixed (≤50% of solid)    1 (25.0%)    2 (40.0%)
        Mixed (>50% of solid)    1 (12.5%)    1 (25.0%)    1 (20.0%)
    Echogenicity                                     0.522
        Marked hypoechoic    5 (62.5%)    2 (50.0%)    2 (40.0%)
        Hypoechoic    3 (37.5%)    1 (25.0%)    3 (60.0%)
        Isoechoic    1 (25.0%)
    Margin 0.118
        Well defined    2 (40.0%)
        Irregular   8 (100%)   4 (100%)    3 (60.0%)
    Calcifications 0.236
        Microcalcification    1 (12.5%)    1 (25.0%)
        Macrocalcification    3 (37.5%)    3 (75.0%) 1 (20%)
        Mixed calcifications 
        No calcification    4 (50.0%) 4 (80%)
    Shape 0.172
        Wider than tall 4 (50%) 3 (75%)   5 (100%)
        Taller than wide 4 (50%) 1 (25%)
    Lymph node involvement 0.003
        Yes   8 (100%)   4 (100%) 1 (20%)
        No 4 (80%)
ATC, anaplastic thyroid cancer; US, ultrasonographic.
Initial FNAB (n=18)
Underestimated
(n=4)
Core bx.
(n=1)
ATC 
diagnosed by:
Surgery
(n=3)
FNA
(n=2)
Core bx.
(n=2)
Surgery
(n=1)
ATC (n=9)
False negative
(n=5)
ATC (n=9)
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less on patients in the initially confirmed ATC (11%) and 
false negative groups (20%) than those in the underestimat-
ed group (75%). 
DISCUSSION
ATC is an extremely aggressive solid tumor that resists most 
therapeutic efforts and is always fatal.1-4,9,10 It contrasts with 
well differentiated thyroid cancer (WDTC), which accounts 
for most thyroid malignancies, with an indolent course and 
good prognosis regardless of the type of treatment.2 The in-
cidence of ATC is decreasing, presumably due to earlier de-
tection of antecedent disease.22 Several studies have revealed 
that potentially curative surgery is the only discriminating 
variable that retains a significant association with prolonged 
hypoechogenicity (9/17, 52.9%) irregular margin (15/17, 
88.2%), internal calcification (9/17, 52.9%), wider than tall 
shape (12/17, 70.5%), and presence of cervical lymph node 
involvement (13/17, 76.4%). The US findings for each group 
were not statistically different, except for lymph node in-
volvement (p=0.003). Mixed composition was more fre-
quently seen in the underestimated (50%) and false nega-
tive groups (60%), compared with the ATC group (12.5%), 
but this was not statistically different (p=0.262). We also 
compared US findings between those in the initially diag-
nosed malignancy group (the cytological ATC and underes-
timated groups) and those in the false negative group, but 
similarly, lymph node involvement was the only statistical-
ly factor that differed between the two groups (Table 2). 
Differences in treatment modalities between the three 
groups are summarized in Table 3. Surgery was performed 
Table 2. Ultrasonographic Findings of Anaplastic Thyroid Cancers According to Two Groups
Malignancy (n=12) False negative (n=5) p value
Diameter (mm) 48.8 40.4    0.139
Age (yrs) 72.0 67.4 0.429
US features
    Composition 0.440
        Solid    9 (75.0%) 2 (40%)
        Mixed (≤50% of solid)  1 (8.3%) 2 (40%)
        Mixed (>50% of solid)    2 (16.7%)
    Echogenicity 0.715
        Marked hypoechoic    7 (58.3%) 1 (20%)
        Hypoechoic    4 (33.3%) 2 (40%)
        Isoechoic  1 (8.3%) 3 (60%)
    Margin 0.074
        Well defined 2 (40%)
        Irregular 12 (100%) 3 (60%)
    Calcifications 0.320
        Microcalcification    2 (16.7%)
        Macrocalcification    6 (50.0%) 1 (20%)
        Mixed calcifications 
        No calcification    4 (33.3%) 4 (80%)
    Shape 0.128
        Wider than tall    7 (58.3%)   5 (100%)
        Taller than wide    5 (41.7%)
    Lymph node involvement 0.002
        Yes 12 (100%) 1 (20%)
        No 4 (80%)
Table 3. Differences between Treatment Modalities Based on the Diagnosis of Initial FNAB
Treatment Modality ATC (n=9) Underestimated (n=4) False negative (n=5)
Surgery 1 (11%) 3 (75%) 1 (20%)
Non-surgical treatments 8 (89%) 1 (25%) 4 (80%)
FNAB, fine needle aspiration biopsy; ATC, anaplastic thyroid cancer.
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cluded. The diagnostic performance in our study was lower 
than others and this may be due to a different study design 
and sample size. Previously, Us-Krasovec, et al.29 reported 
the FNAB results of 113 ATCs for 20 years. They reported 
that 107 patients (107/113, 94.7%) were diagnosed as ma-
lignant and 96 (96/107, 89.7%) were diagnosed as ATC 
through reexamination. If we had reevaluated the pathology 
slides retrospectively perhaps there would have been an in-
crease in diagnostic accuracy. The reason for failures in ob-
taining an accurate diagnosis on FNAB might have been 
due to sampling in areas that consisted of foci of WDTC or 
in areas burdened with necrosis, fibrosis, or hemorrhage.2,29 
In the present study, among the five false negative cases, 
60% (3/5) had both solid and cystic portions on US, which 
contrasted with the 12.5% (1/8) in the initially cytological 
ATC group. It is difficult to obtain adequate cells for diag-
nosis from masses containing both solid and cystic por-
tions,34,35 which could explain why false negative diagnosis 
was frequent in mixed composition.29 According to Luze, et 
al.,31 12% of samples of finally confirmed ATCs contained 
only necrotic material. In order to obtain a representative 
sample, large tumor masses must be aspirated at two or 
three different sites. This is particularly important in differ-
entiated tumors undergoing transformation to ATC, in which 
only small foci of ATC components may be present and 
both well differentiated carcinoma and ATC coexist.1,2,29
Multimodality treatment with combination surgery, radi-
ation and chemotherapy has been reported to improve out-
comes for ATC.2,3,5,18 If tumors can be managed by aggres-
sive surgery with preservation of organ function, adjuvant 
chemotherapy and radiotherapy may be the best option for 
now.36 The majority of patients with ATCs die from aggres-
sive local regional disease, primarily upper airway respirato-
ry failure. For this reason, aggressive local therapy is indicat-
ed in all patients who can tolerate it. Yet complete resection 
of ATC is rarely performed, which gives the best chance of 
long term control and disease free survival. Accordingly, 
more than two-thirds of advanced ATC patients are not ex-
pected to show survival benefits from initial surgery.37 In 
our study, 92.8% (13/14) of pre-op diagnosed ATC cases 
did not undergo surgical treatment. Among the 9 patients in 
the cytological ATC group, only 1 patient underwent surgery, 
whereas 3 out of 4 patients in the underestimated group un-
derwent surgery even though similar US findings were ob-
served. If the patients had been diagnosed with ATCs pre-
operatively, surgery would not have been performed.  
Among the 9 patients in the underestimate and false neg-
survival.8,9,18 But, it was seen in previous studies that sys-
temic metastases were present in 46% of ATC patients at 
presentation, and 68% ATC of patients had metastases di-
agnosed during the course of their illness.19 At this stage, 
complete resection is not meaningful, so patients with inop-
erable disease at diagnosis are considered for combined 
chemotherapy and radiotherapy.10 Thus it is important to 
accurately diagnose ATC before surgery and treatment.16
Grossly, ATC is a nonencapsulated, tan-white, fleshy tu-
mor with a direct extension into the surrounding soft tissue 
of the neck and has regions of necrosis and hemorrhage.23 
The imaging features of ATC reflect these gross findings. 
Large, solid and ill defined masses accompanied by necro-
sis, nodular calcification and cervical lymph node involve-
ment are the common image features of ATC.24 In our study, 
common US features of ATCs included solid (11/17, 64.7%), 
marked hypoechogenicity (9/17, 52.9%), irregular margin 
(15/17, 88.2%), internal calcification (9/17, 52.9%), wider 
than tall shape (12/17, 70.5%) and presence of cervical lymph 
node involvement (13/17, 76.4%). The image features of 
ATCs are not that different from other aggressive forms of 
thyroid cancer, but the prognosis of ATC is significantly 
worse than PDTC. The 5-year disease free survival and 
5-year cause-specific survival of ATC are both 0%, but 
those of PDTC are 51% and 70%.25 PDTC patients survive 
longer, with medial survival being 3.2 years for PDTC and 
3.1 months for ATC. In a previous study, one third of ATC 
patients died of local disease, whereas all patients who died 
of PDTC had distant metastases.26 ATC more frequently in-
vades the surrounding structures and more often involves 
regional lymph nodes; moreover, half the patients with 
ATC present with distant metastases.23
Considering the limitations of US evaluation in studying 
larger masses, CT is much more useful in defining the local 
extent of the disease and detecting lymph node metastases. 
MRI has further added value over CT scan for detecting in-
vasion of vascular, airway and bony structures.23,27 CT or 
MR information on the extent and location of tumor necro-
sis and site of calcification in the tumor is expected to lower 
false negative diagnoses by appreciating indication sites for 
biopsy.28 However, when ATC is clinically suspected, US-
guided cytologic confirmation is initially performed and CT 
or MRI is performed after diagnosis.
The cytological diagnosis accuracy of ATC reported by 
previous reports was 78.7% to 90%.29-33 In the present study, 
the accuracy of initial US-FNAB was 50% (9/18) and in-
creased to 72% (12/18) if the underestimated group was in-
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Cancer Data Base report on 53,856 cases of thyroid carcinoma 
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factors. Cancer 2005;103:1330-5.
8. Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, 
et al. The important role of operations in the management of ana-
plastic thyroid carcinoma. Surgery 2002;131:245-8.
9. Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, 
Shimizu K, et al. Prognostic factors and treatment outcomes of 100 
cases of anaplastic thyroid carcinoma. Thyroid 2011;21:1183-9.
10. Pudney D, Lau H, Ruether JD, Falck V. Clinical experience of the 
multimodality management of anaplastic thyroid cancer and litera-
ture review. Thyroid 2007;17:1243-50. 
11. Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carci-
noma: comparison of conventional radiotherapy and hyperfrac-
tionation chemoradiotherapy in two groups. Am J Clin Oncol 
2002;25:442-6.
12. Haigh PI. Anaplastic thyroid carcinoma. Curr Treat Options Oncol 
2000;1:353-7.
13. Mitchell G, Huddart R, Harmer C. Phase II evaluation of high 
dose accelerated radiotherapy for anaplastic thyroid carcinoma. 
Radiother Oncol 1999;50:33-8.
14. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thomp-
son GB, et al. Anaplastic thyroid carcinoma: a 50-year experience 
at a single institution. Surgery 2001;130:1028-34.
15. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-
Grazio S, Vodnik A. Effect of primary treatment on survival in an-
aplastic thyroid carcinoma. Eur J Surg Oncol 2001;27:260-4.
16. Greenblatt DY, Woltman T, Harter J, Starling J, Mack E, Chen H. 
Fine-needle aspiration optimizes surgical management in patients 
with thyroid cancer. Ann Surg Oncol 2006;13:859-63.
17. American Thyroid Association (ATA) Guidelines Taskforce on 
Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, 
Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised 
American Thyroid Association management guidelines for pa-
tients with thyroid nodules and differentiated thyroid cancer. Thy-
roid 2009;19:1167-214.
18. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey 
JM, et al. Completely resected anaplastic thyroid carcinoma com-
bined with adjuvant chemotherapy and irradiation is associated 
with prolonged survival. Cancer 2001;91:2335-42.
19. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic car-
cinoma of the thyroid: a 45-year comparative study at a single in-
stitution and a review of the significance of p53 and p21. Ann 
Surg 2000;231:329-38.
20. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid 
Cytopathology. Thyroid 2009;19:1159-65. 
21. Rashid OM, Takabe K. The evolution of the role of surgery in the 
management of breast cancer lung metastasis. J Thorac Dis 2012; 
4:420-4. 
22. Boerner SL, Asa SL. Biopsy interpretation of the thyroid. 1st ed. 
Philadelphia (PA): Lippincott Williams & Wilkins, a Wolters Klu-
wer business; 2010.
23. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15: 
78-83.
24. Lee JW, Yoon DY, Choi CS, Chang SK, Yun EJ, Seo YL, et al. 
Anaplastic thyroid carcinoma: computed tomographic differentia-
tion from other thyroid masses. Acta Radiol 2008;49:321-7.
ative groups, 5 patients were diagnosed as having ATCs 
through repeat FNAB or core biopsy. Repeated FNAB and 
core biopsy including immunohistochemical staining and 
flow cytometry analysis2,19,22 were valuable methods when 
suspicions of clinical and imaging findings remained high 
and initial FNAB was inadequate or benign. 
There are some limitations to this study. First, this study 
was based on a retrospective design, and the initial cytology 
results were not reviewed. More over as this study had a 
small sample size, we did not compare the mean survival pe-
riod of each group by different treatment modalities. So we 
did not analyze the survival rate of each group. Second, al-
most all cases of ATC in our study were of large size and ad-
vanced cases. Recently, the wide use of high resolution US 
has provided early detection of thyroid malignancy, and this 
might contribute to an earlier detection of ATC. Han, et al.38 
reported time trends of tumor size and characteristics of 
ATC. They reported that the mean tumor size of ATC de-
creased significantly and the frequencies of coexistent dif-
ferentiated thyroid cancer (DTC) increased over time. The 
mean tumor size of long term survivors was significant 
smaller and the proportion of cases with coexistent DTC 
was much higher in long term survivors than short term 
survivors. So smaller ATC and cases with coexistent DTC 
were increasingly detected, and accordingly, therapeutic ap-
proaches have evolved with growing expectations of long 
term survival for ATC patients.38 
In conclusion, in the present study, the most common US 
features of ATC were a large, solid, irregular shaped mass 
with lymph node involvement. A correct diagnosis of ATC 
by initial US-FNAB was made in 50% of the patients, which 
is significant in that therapeutic surgery can be undertaken 
in lower numbers if correctly diagnosed.
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